4 January 2012 - US rare fibrotic diseases therapies developer Halo Therapeutics LLC said on Wednesday that HT-100 received US Food and Drug Administration (FDA) Orphan Drug status for the treatment of Duchenne muscular dystrophy (DMD).

HT-100, also known as halofuginone, is an orally avail...

 

 

 

You must be logged in to view the whole article.
Click here if you require signing up